Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DHFR | P00374 | 1/20 | 0.46 |
| ▸ | RORA | P35398 | 1/20 | 0.41 |
| ▸ | RORC | P51449 | 1/20 | 0.41 |
| ▸ | RORB | Q92753 | 1/20 | 0.41 |
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 2/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | USP2 | O75604 | 1/20 | 0.40 |
| ▸ | HPGD | P15428 | 1/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6689039 | 0.94 | NPC1 (0.45) | DHFRNPC1TSHRKDM4E | |
| SCHEMBL5260181 | 0.93 | NPC1 (0.50) | DHFRRORARORCRORBNPC1 | |
| SCHEMBL1716008 | 0.91 | CNR2 (0.48) | DHFR | |
| SCHEMBL29949593 | 0.87 | HTR1A (0.44) | — | |
| SCHEMBL6737897 | 0.86 | CNR2 (0.46) | DHFRTSHRKDM4E | |
| SCHEMBL5309142 | 0.85 | HPGD (0.44) | DHFRTSHRUSP2HPGDMAPK1 | |
| SCHEMBL29950001 | 0.84 | TSHR (0.45) | TSHR | |
| SCHEMBL6235260 | 0.82 | TSHR (0.63) | DHFRTSHRKDM4EMAPK1 | |
| SCHEMBL30195005 | 0.81 | TSHR (0.64) | TSHRUSP2HPGDMAPK1 | |
| SCHEMBL6736819 | 0.81 | DHFR (0.43) | DHFRTSHRKDM4EUSP2HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1401443-A4 | NOVEL ANTI-INFECTIVES | SMITHKLINE BEECHAM CORP (US) | 2005-10-26 | — | — | EP | claimed |
| US-20040147739-A1 | Novel anti-infectives | SMITHKLINE BEECHAM CORPORATION | 2004-07-29 | — | — | US | claimed |
| EP-1401443-A1 | NOVEL ANTI-INFECTIVES | SMITHKLINE BEECHAM CORPORATION (US) | 2004-03-31 | — | — | EP | claimed |
| WO-2002098424-A1 | NOVEL ANTI-INFECTIVES | SMITHKLINE BEECHAM CORPORATION (US) | 2002-12-12 | — | — | WO | claimed |
| CN-107141288-B | Evodiamine compounds and preparation method and application thereof | 中山大学 | 2019-12-27 | — | — | CN | disclosed |
| US-9757369-B2 | Heterocyclic GSK-3 allosteric modulators | CONSEJO SUPERIOR DE INVESTIGACIONES CIENTIFICAS (CSIC) (ES) | 2017-09-12 | — | — | US | disclosed |
| US-20170196850-A1 | Heterocyclic GSK-3 Allosteric Modulators | CONSEJO SUPERIOR DE INVESTIGACIONES CIENTIFICAS (CSIC) (ES) | 2017-07-13 | — | — | US | disclosed |
| EP-2769720-B1 | HETEROCYCLIC GSK-3 ALLOSTERIC MODULATORS | CONSEJO SUPERIOR DE INVESTIG CIENTÍFICAS (CSIC) (ES) | 2017-03-29 | — | — | EP | disclosed |
| US-9585879-B2 | Heterocyclic GSK-3 allosteric modulators | CONSEJO SUPERIOR DE INVESTIGACIONES CIENTIFICAS (CSIC) (ES) | 2017-03-07 | — | — | US | disclosed |
| US-20160113918-A1 | Heterocyclic GSK-3 Allosteric Modulators | CONSEJO SUPERIOR DE INVESTIGACIONES CIENTIFICAS (CSIC) (ES) | 2016-04-28 | — | — | US | disclosed |
| US-9193688-B2 | Heterocyclic GSK-3 allosteric modulators | CONSEJO SUPERIOR DE INVESTIGACIONES CIENTIFICAS (ES) | 2015-11-24 | — | — | US | disclosed |
| US-20150057311-A1 | Heterocyclic GSK-3 Allosteric Modulators | CONSEJO SUPERIOR DE INVESTIGACIONES CIENTIFICAS (CSIC) (ES) | 2015-02-26 | — | — | US | disclosed |
| EP-1383750-B1 | UREA DERIVATIVES AS INTEGRIN ALPHA 4 ANTAGONISTS | ALMIRALL LAB (ES) | 2007-09-26 | — | — | EP | disclosed |
| US-7253171-B2 | Urea derivatives as integrin α4 antagonists | LABORATORIOS ALMIRALL, S.A. (ES) | 2007-08-07 | — | — | US | disclosed |
| EP-1401443-A4 | NOVEL ANTI-INFECTIVES | SMITHKLINE BEECHAM CORP (US) | 2005-10-26 | — | — | EP | disclosed |
| US-20040147739-A1 | Novel anti-infectives | SMITHKLINE BEECHAM CORPORATION | 2004-07-29 | — | — | US | disclosed |
| US-20040142982-A1 | Urea derivatives as integrin alpha 4 antagonists | LABORATORIOS ALMIRALL, S.A. (ES) | 2004-07-22 | — | — | US | disclosed |
| EP-1401443-A1 | NOVEL ANTI-INFECTIVES | SMITHKLINE BEECHAM CORPORATION (US) | 2004-03-31 | — | — | EP | disclosed |
| WO-2002098424-A1 | NOVEL ANTI-INFECTIVES | SMITHKLINE BEECHAM CORPORATION (US) | 2002-12-12 | — | — | WO | disclosed |
| US-3969506-A | BRONCHODILATOR | SANDOZ, INC. (US) | 1976-07-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040147739-A1 | Novel anti-infectives | RPL5, RPL7, RPL35 | DHFR 963/4885RORA 1573/4885RORC 1516/4885 |
| US-20170196850-A1 | Heterocyclic GSK-3 Allosteric Modulators | GSK3B, GSK3A, GSKIP | DHFR 3478/4885RORA 145/4885RORC 81/4885 |
| US-20160113918-A1 | Heterocyclic GSK-3 Allosteric Modulators | GSK3B, GSK3A, GSKIP | DHFR 3478/4885RORA 145/4885RORC 81/4885 |
| US-20040142982-A1 | Urea derivatives as integrin alpha 4 antagonists | ITGA4, ITGB4, ITGA1 | DHFR 4538/4885RORA 2958/4885RORC 3553/4885 |
| US-20150057311-A1 | Heterocyclic GSK-3 Allosteric Modulators | GSK3B, GSK3A, GSKIP | DHFR 3478/4885RORA 145/4885RORC 81/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.